WHO ICTRP trial
Phase 1 study of quizartinib
JPRN-jRCT2080223088 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2080223088 |
|---|---|
| Public title | Phase 1 study of quizartinib |
| Scientific title | A Phase 1, Open-Label, Dose Escalation Study of Quizartinib, An Oral FLT3 Inhibitor, in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia |
| Primary sponsor | DAIICHI SANKYO Co.,Ltd. |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 1 |
| Countries | Japan |
| Conditions | Relapsed or refractory AML |
| Interventions | investigational material(s) Generic name etc : AC220 INN of investigational material : Quizartinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Oral administration once… |
| Registration date | Jan 27, 2016 |
| Target size | 21 |
| Secondary IDs | NCT02675478;JapicCTI-163142 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: